Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 271 participants.

Also called NCT05476354

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 271 participants (enrolled count) (from the registry)
Sponsor
  • Handok Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05476354
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05476354. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-05 (actual); primary completion 2023-04-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients
Condition
Essential Hypertension
Intervention (Drug)
Irbesartan/Amlodipine low
Intervention (Drug)
Irbesartan/Amlodipine high
Intervention (Drug)
Irbesartan
Lead sponsor
Handok Inc. (class: industry)

Record details

Record id
cardio:ct-nct05476354
Content hash
c4b2d2e0eb62f273cd3d8b8b8f9b567f5b61b85e25165d18b3f3111a61868ed5